Erastin: Ferroptosis Inducer Targeting RAS/BRAF-Mutant Tumors

Executive Summary: Erastin (SKU B1524) is a small molecule that selectively induces ferroptosis, an iron-dependent, non-apoptotic cell death, in tumor cells with KRAS or BRAF mutations (APExBIO product page). It disrupts redox homeostasis by inhibiting the cystine/glutamate antiporter system Xc⁻ and modulating VDAC channels, leading to lethal accumulation of intracellular ROS (Gupta et al., 2025). Erastin’s action is independent of caspase pathways, offering a unique tool for dissecting oxidative stress and cell death mechanisms. Widely adopted in research, it is stable as a solid at -20°C and soluble in DMSO at concentrations ≥10.92 mg/mL. Use of Erastin enables robust, reproducible ferroptosis induction in engineered tumor models, facilitating studies of cancer biology and translational oncology.

Biological Rationale

Ferroptosis is a regulated cell death process characterized by iron-dependent lipid peroxidation and distinct from apoptosis or necrosis (Gupta et al., 2025). Tumor cells with activating mutations in the RAS family (HRAS, KRAS) or BRAF genes exhibit heightened susceptibility to oxidative damage. Conventional therapies often fail to target these oncogenic pathways effectively (Erastin: A Precision Ferroptosis Inducer). Erastin specifically exploits this vulnerability by inducing ferroptosis, resulting in cell death independently of caspases or the classical apoptotic machinery. This approach is particularly relevant for chemoresistant cancers, such as pancreatic and certain lung tumors, where RAS pathway alterations are prevalent. By leveraging iron metabolism and redox regulation, Erastin enables new experimental and therapeutic strategies for cancer biology research.

Mechanism of Action of Erastin

Erastin’s mechanism centers on the inhibition of the cystine/glutamate antiporter system Xc⁻ (SLC7A11/xCT), blocking cystine import and depleting intracellular glutathione (GSH) (APExBIO). This depletion impairs glutathione peroxidase 4 (GPX4) activity, resulting in unchecked lipid ROS accumulation and ferroptotic cell death. Erastin also directly binds to and modulates voltage-dependent anion channels (VDACs) in the mitochondrial outer membrane, further enhancing ROS generation and disrupting mitochondrial function. Notably, Erastin-induced death is caspase-independent, distinguishing it from apoptosis (Erastin: A Ferroptosis Inducer Transforming Cancer Biology). This dual mechanism ensures specificity for cells with RAS/BRAF mutations, as these cells have elevated basal oxidative stress and are less able to compensate for redox disruption.

Evidence & Benchmarks

• Erastin induces ferroptosis by inhibiting system Xc⁻ and depleting glutathione in tumor cells with KRAS or BRAF mutations (Gupta et al., 2025).
• Treatment with 10 μM Erastin for 24 hours leads to significant ROS accumulation and lipid peroxidation in HT-1080 fibrosarcoma cells (APExBIO).
• Ferroptosis induced by Erastin is iron-dependent and not reversed by caspase inhibitors, confirming a non-apoptotic mechanism (Erastin (SKU B1524): Reliable Ferroptosis Induction).
• Erastin’s effect is potentiated when combined with agents that elevate intracellular iron or deplete antioxidant defenses (Gupta et al., 2025).
• Systematic reviews confirm Erastin’s reproducibility across cell lines and its value as a standard in oxidative stress assays (Erastin and the Translational Edge).

Applications, Limits & Misconceptions

Erastin is widely used in:

• Cancer biology research targeting ferroptosis in RAS/BRAF-mutant tumor cells.
• Oxidative stress assays to dissect iron-dependent cell death pathways.
• Preclinical studies modeling therapeutic resistance and caspase-independent mechanisms.

It is not effective in cell types lacking system Xc⁻ expression or in those with robust alternative antioxidant systems. Erastin’s action is not equivalent to classical necrosis or apoptosis in either mechanism or morphology (Erastin and the Executional Phase of Ferroptosis). This article extends previous coverage by providing a structured, peer-reviewed evidence synthesis for workflow integration and highlighting storage/stability constraints that impact experimental reproducibility.

Common Pitfalls or Misconceptions

• Erastin does not induce apoptosis or necrosis; its action is ferroptosis-specific.
• It is ineffective in cells lacking functional system Xc⁻ (e.g., certain non-tumor cell lines).
• Long-term solution storage (>24 hours) leads to loss of potency due to instability in DMSO.
• Water or ethanol cannot be used as solvents; only DMSO is recommended at ≥10.92 mg/mL with gentle warming.
• Erastin’s effects are iron-dependent; chelation of iron blocks activity.

Workflow Integration & Parameters

For experimental use, Erastin (SKU B1524) from APExBIO is supplied as a solid, with optimal storage at -20°C. Working solutions should be freshly prepared in DMSO at concentrations ≥10.92 mg/mL and gently warmed to dissolve. Standard protocols employ 10 μM Erastin for 24 hours in engineered human tumor or HT-1080 fibrosarcoma cells. Assays are typically performed under normoxic conditions with iron-replete media. Endpoints measured include ROS accumulation, lipid peroxidation, mitochondrial membrane potential, and cell viability (Gupta et al., 2025). For troubleshooting and advanced designs, see the extended guide in Erastin: A Precision Ferroptosis Inducer, which this article updates with new stability and benchmarking data.

Conclusion & Outlook

Erastin remains a cornerstone reagent for ferroptosis research and cancer biology, providing selective, reproducible induction of iron-dependent, non-apoptotic cell death in RAS/BRAF-mutant tumor models. Ongoing developments in targeted therapies, such as folate receptor-guided nanoactivators, reinforce the translational relevance of ferroptosis in overcoming chemoresistance (Gupta et al., 2025). As new mechanistic insights and therapeutic strategies emerge, Erastin’s role as a benchmark tool will continue to expand. For full product specifications and ordering, refer to the Erastin product page at APExBIO.